{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:51Z","timestamp":1782409671399,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SCRUM-Japan Funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hematologic malignancies exhibit marked biological heterogeneity that is often insufficiently characterized by genomic profiling alone. Integrated multi-omics approaches are required to enable more accurate prognostic stratification, elucidate resistance mechanisms, and identify therapeutic vulnerabilities across lymphoma, leukemia, and plasma cell neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SCRUM-Japan MONSTAR3 is a nationwide, prospective, integrated multi-omics platform. The hematology cohort aims to enroll 400 patients with newly diagnosed or relapsed\/refractory hematologic malignancies. Tumor specimens\u2014including bone marrow aspirates\/biopsies or lymph node tissues\u2014are collected at diagnosis and at relapse. The multi-omics workflow encompasses whole-exome sequencing, whole-transcriptome sequencing, spatial transcriptomics, plasma proteomics, metabolomics, microbiome analysis, and tumor-informed measurable residual disease (MRD) monitoring. MRD is assessed using next-generation sequencing-based immunoglobulin heavy (IgH) and T-cell receptor (TCR) rearrangement analysis for lymphoid malignancies and whole-genome sequencing\u2013based variant tracking for myeloid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patient enrollment began in December 2024, followed by nationwide multicenter activation in November 2025. Multi-omics analyses have been implemented in a stepwise manner. Early operational indicators, including biospecimen acquisition, data quality control, and initiation of molecular assays, demonstrate the feasibility of coordinated nationwide deployment of this complex platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The MONSTAR3 hematology cohort represents the first nationwide integrated multi-omics initiative dedicated to hematologic malignancies. Its large scale, standardized biospecimen framework, and capacity to incorporate emerging technologies provide a robust infrastructure for molecular stratification, longitudinal disease monitoring, and hypothesis-driven interventional research, thereby advancing clinically actionable precision hematology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03049-4","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T18:01:01Z","timestamp":1779559261000},"page":"1108-1116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies"],"prefix":"10.1007","volume":"31","author":[{"given":"Kensuke","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-1636","authenticated-orcid":false,"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yoshimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Harima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Fukatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Araie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Ohwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayoshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuho","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riu","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Dodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Horasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"3049_CR1","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1111\/cas.15427","volume":"113","author":"S Fukuhara","year":"2022","unstructured":"Fukuhara S, Oshikawa-Kumade Y, Kogure Y et al (2022) Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci 113:2763\u20132777. https:\/\/doi.org\/10.1111\/cas.15427","journal-title":"Cancer Sci"},{"key":"3049_CR2","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood.2022015854","volume":"140","author":"L de Leval","year":"2022","unstructured":"de Leval L, Alizadeh AA, Bergsagel PL et al (2022) Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 140:2193\u20132227. https:\/\/doi.org\/10.1182\/blood.2022015854","journal-title":"Blood"},{"key":"3049_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3960\/jslrt.22027","volume":"62","author":"K Miyawaki","year":"2022","unstructured":"Miyawaki K, Sugio T (2022) Lymphoma microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification. J Clin Exp Hematop 62:127\u2013135. https:\/\/doi.org\/10.3960\/jslrt.22027","journal-title":"J Clin Exp Hematop"},{"key":"3049_CR4","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1111\/cas.15132","volume":"112","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Fujisawa T, Taniguchi H et al (2021) SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: path to the realization of biomarker-guided precision oncology in advanced solid tumors. Cancer Sci 112:4425\u20134432. https:\/\/doi.org\/10.1111\/cas.15132","journal-title":"Cancer Sci"},{"key":"3049_CR5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","volume":"26","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26:1859\u20131864. https:\/\/doi.org\/10.1038\/s41591-020-1063-5","journal-title":"Nat Med"},{"key":"3049_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00688","volume":"7","author":"Y Aoki","year":"2023","unstructured":"Aoki Y, Nakamura Y, Denda T et al (2023) Clinical validation of plasma-based genotyping for RAS and BRAF V600E mutation in metastatic colorectal cancer: SCRUM-Japan GOZILA substudy. JCO Precis Oncol 7:e2200688. https:\/\/doi.org\/10.1200\/po.22.00688","journal-title":"JCO Precis Oncol"},{"key":"3049_CR7","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","volume":"112","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi H, Nakamura Y, Kotani D et al (2021) CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci 112:2915\u20132920. https:\/\/doi.org\/10.1111\/cas.14926","journal-title":"Cancer Sci"},{"key":"3049_CR8","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/2159-8290.cd-24-0206","volume":"14","author":"T Hashimoto","year":"2024","unstructured":"Hashimoto T, Nakamura Y, Fujisawa T et al (2024) The SCRUM-MONSTAR cancer-omics ecosystem: striving for a quantum leap in precision medicine. Cancer Discov 14:2243\u20132261. https:\/\/doi.org\/10.1158\/2159-8290.cd-24-0206","journal-title":"Cancer Discov"},{"key":"3049_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.42970","volume":"7","author":"D Owen","year":"2024","unstructured":"Owen D, Ben-Shachar R, Feliciano J et al (2024) Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer. JAMA Netw Open 7:e2442970. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.42970","journal-title":"JAMA Netw Open"},{"key":"3049_CR10","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/jco.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC et al (2018) Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 36:2845\u20132853. https:\/\/doi.org\/10.1200\/jco.2018.78.5246","journal-title":"J Clin Oncol"},{"key":"3049_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H et al (2017) Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia. JAMA Oncol 3:e170580. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580","journal-title":"JAMA Oncol"},{"key":"3049_CR12","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJM van Dongen","year":"2015","unstructured":"van Dongen JJM, van der Velden VHJ, Br\u00fcggemann M et al (2015) Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125:3996\u20134009. https:\/\/doi.org\/10.1182\/blood-2015-03-580027","journal-title":"Blood"},{"key":"3049_CR13","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J et al (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132:2456\u20132464. https:\/\/doi.org\/10.1182\/blood-2018-06-858613","journal-title":"Blood"},{"key":"3049_CR14","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM et al (2016) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8:364\u2013155. https:\/\/doi.org\/10.1126\/scitranslmed.aai8545","journal-title":"Sci Transl Med"},{"key":"3049_CR15","doi-asserted-by":"publisher","first-page":"21194","DOI":"10.1073\/pnas.1118357109","volume":"108","author":"AC Logan","year":"2011","unstructured":"Logan AC, Gao H, Wang C et al (2011) High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A 108:21194\u201321199. https:\/\/doi.org\/10.1073\/pnas.1118357109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3049_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/nejmoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D et al (2018) Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378:1189\u20131199. https:\/\/doi.org\/10.1056\/nejmoa1716863","journal-title":"N Engl J Med"},{"key":"3049_CR17","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ et al (2021) 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138:2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"key":"3049_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07077-9","volume":"20","author":"T Ching","year":"2020","unstructured":"Ching T, Duncan ME, Newman-Eerkes T et al (2020) Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer 20:612. https:\/\/doi.org\/10.1186\/s12885-020-07077-9","journal-title":"BMC Cancer"},{"key":"3049_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/cpt.3645","volume":"118","author":"K Matsuda","year":"2025","unstructured":"Matsuda K, Nonami A, Shinohara K et al (2025) Regulatory approval of CAR\u2010T cell and BsAb products for lymphoid neoplasms in the US, EU, and Japan. Clin Pharmacol Ther 118:118\u2013127. https:\/\/doi.org\/10.1002\/cpt.3645","journal-title":"Clin Pharmacol Ther"},{"key":"3049_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26614-z","volume":"12","author":"MV Hunter","year":"2021","unstructured":"Hunter MV, Moncada R, Weiss JM et al (2021) Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface. Nat Commun 12:6278. https:\/\/doi.org\/10.1038\/s41467-021-26614-z","journal-title":"Nat Commun"},{"key":"3049_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02040-9","volume":"23","author":"Y Jin","year":"2024","unstructured":"Jin Y, Zuo Y, Li G et al (2024) Advances in spatial transcriptomics and its applications in cancer research. Mol Cancer 23:129. https:\/\/doi.org\/10.1186\/s12943-024-02040-9","journal-title":"Mol Cancer"},{"key":"3049_CR22","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/s41588-025-02353-5","volume":"57","author":"Y Dai","year":"2025","unstructured":"Dai Y, Kizhakeyil A, Chihara D et al (2025) Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma. Nat Genet 57:2715\u20132727. https:\/\/doi.org\/10.1038\/s41588-025-02353-5","journal-title":"Nat Genet"},{"key":"3049_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-025-08975-z","volume":"8","author":"E Mui\u00f1os-Lopez","year":"2025","unstructured":"Mui\u00f1os-Lopez E, Lopez-Perez AR, Sudupe L et al (2025) Characterization of the bone marrow architecture of multiple myeloma using spatial transcriptomics. Commun Biol 8:1620. https:\/\/doi.org\/10.1038\/s42003-025-08975-z","journal-title":"Commun Biol"},{"key":"3049_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","volume":"22","author":"MME de Jong","year":"2021","unstructured":"de Jong MME, Kellermayer Z, Papazian N et al (2021) The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol 22:769\u2013780. https:\/\/doi.org\/10.1038\/s41590-021-00931-3","journal-title":"Nat Immunol"},{"key":"3049_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192","journal-title":"PLoS ONE"},{"key":"3049_CR26","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1007\/s10147-024-02611-2","volume":"29","author":"N Tagami","year":"2024","unstructured":"Tagami N, Yuda J, Goto Y (2024) Current status of BAFF targeting immunotherapy in b-cell neoplasm. Int J Clin Oncol 29:1676\u20131683. https:\/\/doi.org\/10.1007\/s10147-024-02611-2","journal-title":"Int J Clin Oncol"},{"key":"3049_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/10428194.2025.2569759","volume":"67","author":"M Oura","year":"2026","unstructured":"Oura M, Ikeda D, Aikawa S et al (2026) Soluble BCMA as a biomarker reflecting tumor volume and treatment response in Waldenstr\u00f6m macroglobulinemia. Leuk Lymphoma 67:85\u201396. https:\/\/doi.org\/10.1080\/10428194.2025.2569759","journal-title":"Leuk Lymphoma"},{"key":"3049_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ajh.27225","volume":"99","author":"BA Costa","year":"2024","unstructured":"Costa BA, Ortiz RJ, Lesokhin AM et al (2024) Soluble b\u2010cell maturation antigen in multiple myeloma. Am J Hematol 99:727\u2013738. https:\/\/doi.org\/10.1002\/ajh.27225","journal-title":"Am J Hematol"},{"key":"3049_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/metabo9070123","volume":"9","author":"AH Emwas","year":"2019","unstructured":"Emwas AH, Roy R, McKay RT et al (2019) NMR spectroscopy for metabolomics research. Metabolites 9:123. https:\/\/doi.org\/10.3390\/metabo9070123","journal-title":"Metabolites"},{"key":"3049_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, Dzutsev A, Stewart CA et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342:967\u2013970. https:\/\/doi.org\/10.1126\/science.1240527","journal-title":"Science"},{"key":"3049_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"key":"3049_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104\u2013108. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"key":"3049_CR33","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/biomedicines13071654","volume":"13","author":"R Khoury","year":"2025","unstructured":"Khoury R, Raffoul C, Khater C et al (2025) Precision medicine in hematologic malignancies: evolving concepts and clinical applications. Biomedicines 13:1654. https:\/\/doi.org\/10.3390\/biomedicines13071654","journal-title":"Biomedicines"},{"key":"3049_CR34","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41591-025-03715-6","volume":"31","author":"N Miglino","year":"2025","unstructured":"Miglino N, Toussaint NC, Ring A et al (2025) Feasibility of multiomics tumor profiling for guiding treatment of melanoma. Nat Med 31:2430\u20132441. https:\/\/doi.org\/10.1038\/s41591-025-03715-6","journal-title":"Nat Med"},{"key":"3049_CR35","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, Schroeder MC, O\u2019Laughlin M et al (2021) Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med 384:924\u2013935. https:\/\/doi.org\/10.1056\/NEJMoa2024534","journal-title":"N Engl J Med"},{"key":"3049_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/ijms26010071","volume":"26","author":"F Ahmed","year":"2024","unstructured":"Ahmed F, Zhong J (2024) Advances in DNA\/RNA sequencing and their applications in acute myeloid leukemia (AML). Int J Mol Sci 26:71. https:\/\/doi.org\/10.3390\/ijms26010071","journal-title":"Int J Mol Sci"},{"key":"3049_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.842507","volume":"9","author":"E Berglund","year":"2022","unstructured":"Berglund E, Barbany G, Orsmark-Pietras C et al (2022) A study protocol for validation and implementation of whole-genome and -transcriptome sequencing as a comprehensive precision diagnostic test in acute leukemias. Front Med 9:842507. https:\/\/doi.org\/10.3389\/fmed.2022.842507","journal-title":"Front Med"},{"key":"3049_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/13543784.2025.2587276","volume":"34","author":"J Nolan","year":"2025","unstructured":"Nolan J, Kuruvilla J (2025) Diffuse large B-cell lymphoma: What clinical progress have we seen in the last 5 years? Expert Opin Investig Drugs 34:831\u2013853. https:\/\/doi.org\/10.1080\/13543784.2025.2587276","journal-title":"Expert Opin Investig Drugs"},{"key":"3049_CR39","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","volume":"29","author":"PJ O'Dwyer","year":"2023","unstructured":"O\u2019Dwyer PJ, Gray RJ, Flaherty KT et al (2023) The NCI-MATCH trial: lessons for precision oncology. Nat Med 29:1349\u20131357. https:\/\/doi.org\/10.1038\/s41591-023-02379-4","journal-title":"Nat Med"},{"key":"3049_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10147-026-03001-6","volume":"20","author":"T Shibuki","year":"2025","unstructured":"Shibuki T, Yamashita R, Hashimoto T et al (2025) Clinical Development of Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED) using Liquid Biopsy Multiomics with Artificial Intelligence (AI). Int J Clin Oncol 20:23. https:\/\/doi.org\/10.1007\/s10147-026-03001-6","journal-title":"Int J Clin Oncol"},{"key":"3049_CR41","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/jjco\/hyad117","volume":"53","author":"K Matsuda","year":"2023","unstructured":"Matsuda K, Nagai S, Sugimoto K (2023) Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective. Jpn J Clin Oncol 53:1125\u20131129. https:\/\/doi.org\/10.1093\/jjco\/hyad117","journal-title":"Jpn J Clin Oncol"},{"key":"3049_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/cpt.3440","volume":"117","author":"K Matsuda","year":"2025","unstructured":"Matsuda K, Nagai S, Sugimoto K (2025) Characteristics of drugs from non-global companies for hematologic malignancies and impact on global regulatory approval. Clin Pharmacol Ther 117:232\u2013239. https:\/\/doi.org\/10.1002\/cpt.3440","journal-title":"Clin Pharmacol Ther"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03049-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03049-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03049-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:19:30Z","timestamp":1782407970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03049-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3049"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03049-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no direct competing interests related to this study. However, as the present work utilizes data generated within the MONSTAR3 framework, potential indirect competing interests may exist. J. Yuda has received research funding from Amgen Inc., AbbVie Inc., AstraZeneca plc, Bristol Myers Squibb, BrighPath Bio, Celaid Therapeutics, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Genmab A\/S, Incyte Corporation, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Novartis AG, Sanofi S.A., Sumitomo Pharma Co., Ltd., and Takeda Pharmaceutical Company Limited. T. Ikezoe has served in advisory roles for Chugai Pharmaceutical Co., Ltd. and Alexion Pharmaceuticals, Inc., and has received research funding from Sumitomo Pharma Co., Ltd., Amgen Inc., GlaxoSmithKline plc, Novartis AG, Takeda Pharmaceutical Company Limited, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Sanofi S.A., Astellas Pharma Inc., and Nippon Shinyaku Co., Ltd. N. Hosono has received honoraria from Astellas Pharma Inc., Nippon Shinyaku Co., Ltd., AbbVie Inc., and Daiichi Sankyo Company, Limited. T. Fujisawa has received honoraria from Amelieff Inc., AstraZeneca plc, and MSD K.K. T. Hashimoto has served in an advisory role for Guardant Health, Inc., and has received honoraria from Cytogen Japan, Takeda Pharmaceutical Company Limited, Myriad Genetics, Inc., and Miyarisan Pharmaceutical Co., Ltd. T. Shibuki has received honoraria from AstraZeneca plc and Novartis AG. M. Imai has received honoraria from Caris Life Sciences, Guardant Health, Inc., Chugai Pharmaceutical Co., Ltd., and Exact Sciences Corporation, and has received research funding from Exact Sciences Corporation. M. Nagamine has served in an advisory role for SRL, Inc. Y. Nakamura has served in advisory roles for Guardant Health, Inc., Natera, Inc., Exact Sciences Corporation, Tempus AI, Inc., Pfizer Inc., and Shionogi & Co., Ltd., and has received honoraria from MSD K.K., Merck Biopharma Co., Ltd., Daiichi Sankyo Company, Limited, Chugai Pharmaceutical Co., Ltd., and Guardant Health, Inc. H. Bando has received honoraria from Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Guardant Health, Inc., and has received research funding from Takeda Pharmaceutical Company Limited and GlaxoSmithKline plc. T. Yoshino has received honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Merck Biopharma Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Sumitomo Corporation, and Indivumed GmbH, and has received research funding from Amgen Inc., Bristol Myers Squibb, Caris Life Sciences (Caris MPI), Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Exact Sciences Corporation, FALCO Biosystems Ltd., Medical & Biological Laboratories Co., Ltd., Merus N.V., Miyarisan Pharmaceutical Co., Ltd., Molecular Health GmbH, MSD K.K., Natera, Inc., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Roche Diagnostics GmbH, Sanofi S.A., Sysmex Corporation, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, and Merck Biopharma Co., Ltd. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the National Cancer Center Hospital East (Approval No. 2023-354). All study procedures are conducted in accordance with the principles of the Declaration of Helsinki and Japan\u2019s Ethical Guidelines for Medical and Health Research Involving Human Subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants prior to enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}